Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 63.63 USD -2.94% Market Closed
Market Cap: $9.9B

ROE

3.7%
Current
Declining
by 6.8%
vs 3-y average of 10.5%

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
3.7%
=
Net Income
$76.8m
/
Avg Total Equity
$2.1B

Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.

ROE
3.7%
=
Net Income
$76.8m
/
Avg Total Equity
$2.1B

Peer Comparison

Country Company Market Cap ROE
US
Bio-Techne Corp
NASDAQ:TECH
9.9B USD
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.2T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
223.2B USD
Loading...
US
Danaher Corp
NYSE:DHR
154.9B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
81.3T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.3B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.3B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
37.4B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.2B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.6B EUR
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
40th
Based on 13 668 companies
40th percentile
3.7%
Low
-155 749.7% — -2%
Typical Range
-2% — 15.9%
High
15.9% — 143 206.7%
Distribution Statistics
the United States of America
Min -155 749.7%
30th Percentile -2%
Median 8.2%
70th Percentile 15.9%
Max 143 206.7%

Bio-Techne Corp
Glance View

Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.

TECH Intrinsic Value
HIDDEN
Show
What is Return on Equity?
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
How is ROE calculated?

ROE is calculated by dividing the Net Income by the Avg Total Equity.

ROE
3.7%
=
Net Income
$76.8m
/
Avg Total Equity
$2.1B
What is Bio-Techne Corp's current ROE?

The current ROE for Bio-Techne Corp is 3.7%, which is below its 3-year median of 10.5%.

How has ROE changed over time?

Over the last 3 years, Bio-Techne Corp’s ROE has decreased from 17.2% to 3.7%. During this period, it reached a low of 3.7% on Jun 30, 2025 and a high of 17.2% on Sep 30, 2022.

Back to Top